From London: Cancer Research Horizons takes research from Cancer Research UK (and beyond) and invests in the translational work and companies that turn it into cures

Jefferies London: Ipsen has done a string of deals over recent years, including acquiring ImCheck last month. CEO David Loew says the company has billions in firepower to do more

Jefferies London: Terns' CEO Amy Burroughs previews the company's upcoming ASH presentation for the allosteric BCR::ABL1 inhibitor tern-701 in relapsed/refractory cml

Jefferies London: Affinity Asset Advisors' Patrick Nosker shares a public investor's perspective on biotech and walks us through a few of his firm's top positions

Jefferies London: Medicxi Announced a €500 Million Fund V ahead of this week's conference - Co-founder Giovanni Mariggi describes the firm's asset-centric approach to investing in biotech

Jefferies London: Olema Oncology more than doubled yesterday when Roche announced surprise data for its oral SERD - the CEO reacts and shares the development program for Olema's competing asset

Jefferies London: Zealand Pharma CEO Adam Steensberg believes that amylins will overtake GLPs as the backbones of obesity treatments in the future

Jefferies London: Nanobiotix has a new platform that is meant to help RNA/DNA-based therapies, gene therapies, oncolytic viruses and other liver-delivered medicines have better efficacy

Jefferies London: Jefferies Global Chairman of Healthcare Philip Ross discusses the environment for biotech and deals

Jefferies London: Chief Scientific Officer Tony Wood covers the latest highlights in GSK's pipeline, including oncology, respiratory, and inflammation

Jefferies London: Zymeworks had double-news during London Life Science Week - a P3 success for its HER2 bispecific in gastroesophageal cancer and it also launched a new royalty model

Jefferies London: Protagonist Therapeutics CEO Dinesh Patel responds to takeout speculation and discusses the company's programs and culture of partnering

Jefferies London: BeOne Medicines announced a phase 3 success for its HER2 bispecific today in gastric cancer. John Olyer walks us through that and the whole pipeline

Jefferies London: Sofinnova Partners announced a new $750M fund XI today that will invest in early stage companies in biotech

Jefferies London: Jefferies M&A Banker Chris Roop shares his take on the environment for deals in biotech

Legend Biotech CEO Ying Huang shares a post-earnings update from the company's new R&D Center in Philadelphia

Apogee will have at lest four key trial readouts for its half-life optimized IL-13 program next year, including monotherapy trials and in combination with OX40L and TSLP.

Avalo Therapeutics is developing a high affinity IL-1β for hidradenitis suppurativa - key phase 2 data will come next year

Stifel's Head of Global Equity Capital Markets Seth Rubin describes the investor feedback he is hearing about the sector lately and the fundraising environment for companies

Sionna Therapeutics is trying to improve the treatment paradigm for cystic fibrosis by targeting NBD1, a nucleotide binding-domain of the CFTR protein, and restore healthy function for all